Phase 2 of CTP-543 Trial Brings Positive News
Positive results have been reported following the completion of the CTP-543 Phase 2 trial. More than 75% of patients receiving two daily
The Promising Treatment CTP-543: Once or Twice Daily?
Concert Pharmaceutical's research team has recently initiated open label trials to determine the optimal dosage rate of the compound CTP-543 for those with
Concert Pharmaceuticals Reports on New Treatment for Alopecia Areata
Concert Pharmaceuticals is a leading company for the development of treatments similar to topical tofacitinib and topical ruxolitinib, both of which are